[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0614475B8 - polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo - Google Patents

polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo

Info

Publication number
BRPI0614475B8
BRPI0614475B8 BRPI0614475A BRPI0614475A BRPI0614475B8 BR PI0614475 B8 BRPI0614475 B8 BR PI0614475B8 BR PI0614475 A BRPI0614475 A BR PI0614475A BR PI0614475 A BRPI0614475 A BR PI0614475A BR PI0614475 B8 BRPI0614475 B8 BR PI0614475B8
Authority
BR
Brazil
Prior art keywords
antibody
cdnas
compositions
further provides
expression system
Prior art date
Application number
BRPI0614475A
Other languages
English (en)
Inventor
Hull Anna
Mett Vadim
Yusibov Vidadi
Original Assignee
Fraunhofer Usa Inc
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Usa Inc, Ibio Inc filed Critical Fraunhofer Usa Inc
Publication of BRPI0614475A2 publication Critical patent/BRPI0614475A2/pt
Publication of BRPI0614475B1 publication Critical patent/BRPI0614475B1/pt
Publication of BRPI0614475B8 publication Critical patent/BRPI0614475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composições e processos para a produção de imunoglobulinas. a presente invenção refere-se a oligonucleotídeos para o isolamento de cdnas de anticorpos humanos partindo de células ou linhagens de células, tais como hibridomas. a invenção fornece ainda cdnas que codificam pelo menos uma cdr fornecida de uma cadeia pesada ou de uma cadeia leve de um anticorpo monoclonal humano que se liga ao antígeno protetor de b. anthracis; e cdnas que codificam pelo menos uma cdr fornecida de uma cadeia pesada ou de uma cadeia leve de um anticorpo monoclonal humano que se liga ao fator letal de b. anthracis. a invenção fornece ainda vetores de expressão que contêm um ou mais cdnas isolados de acordo com os processos da invenção, células hospedeiras que expressam um ou mais cdnas da invenção e plantas e animais transgênicos que expressam um ou mais cdnas da invenção. em certas modalidades da invenção, o sistema de expressão é um sistema de expressão baseado em plantas. a invenção fornece ainda composições de anticorpos que compreendem um ou mais anticorpos produzidos através de expressão de um cdna isolado de acordo com os processos da invenção em um sistema de expressão adequado. são adicionalmente abrangidos na invenção kits que contêm uma ou mais das composições fornecidas, assim como processos de produção e uso das composições fornecidas.
BRPI0614475A 2005-08-03 2006-08-03 polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo BRPI0614475B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70565305P 2005-08-03 2005-08-03
US60/705,653 2005-08-03
PCT/US2006/030545 WO2007117264A2 (en) 2005-08-03 2006-08-03 Compositions and methods for production of immunoglobulins

Publications (3)

Publication Number Publication Date
BRPI0614475A2 BRPI0614475A2 (pt) 2011-03-29
BRPI0614475B1 BRPI0614475B1 (pt) 2018-04-24
BRPI0614475B8 true BRPI0614475B8 (pt) 2021-05-25

Family

ID=38581506

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614475A BRPI0614475B8 (pt) 2005-08-03 2006-08-03 polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo

Country Status (10)

Country Link
US (1) US8962278B2 (pt)
EP (1) EP1919504B1 (pt)
JP (1) JP2009502207A (pt)
KR (1) KR101446025B1 (pt)
CN (1) CN101378781B (pt)
AU (1) AU2006341615A1 (pt)
BR (1) BRPI0614475B8 (pt)
CA (1) CA2616859C (pt)
IL (1) IL189067A0 (pt)
WO (1) WO2007117264A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
CA2749572A1 (en) * 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010144799A2 (en) * 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Methods and compositions for diagnostic assays for measuring cell mediated immune response
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
GB2480298A (en) * 2010-05-13 2011-11-16 Secr Defence Antibodies against Bacillus anthracis
RU2470307C1 (ru) * 2011-11-09 2012-12-20 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ определения наличия протективного антигена сибирской язвы на основе иммунодетекции, сопряженной с полимеразной цепной реакцией
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
WO2018127709A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CA3082297A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CA3228786A1 (en) * 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd25 antibody

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1997568A (en) * 1933-07-27 1935-04-16 Gen Electric Co Ltd Electric ship propulsion system
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS61176721A (ja) * 1985-01-31 1986-08-08 Mochizuki Motor Kk マンホ−ル蓋の開閉運搬装置
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
DE3850683T2 (de) 1987-02-09 1994-10-27 Lubrizol Genetics Inc Hybrides RNS-Virus.
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5316931A (en) * 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2638359A1 (fr) * 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7005560B1 (en) * 1989-10-27 2006-02-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
AU662148B2 (en) * 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
KR0137806B1 (ko) * 1991-07-25 1998-04-30 케네쓰 제이. 울코트 사람의 질병 치료를 위한 재조합 항체
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU684041B2 (en) * 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
AU3737893A (en) * 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5702892A (en) * 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
EP0827409A1 (en) * 1995-05-15 1998-03-11 Cedars-Sinai Medical Center Compositions and methods for inhibiting xenograft rejection
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6103511A (en) * 1996-10-04 2000-08-15 University Of Georgia Research Foundation, Inc. Lichenase and coding sequences
EP0931153A1 (en) 1996-10-04 1999-07-28 University Of Georgia Research Foundation, Inc. Fungal lichenase and coding sequences
CA2286330C (en) 1997-04-07 2008-06-10 Genentech, Inc. Anti-vegf antibodies
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US6037456A (en) * 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
AU759813B2 (en) * 1998-08-11 2003-05-01 Kentucky Bioprocessing, Llc Method for recovering proteins from the interstitial fluid of plant tissues
CA2344269A1 (en) 1998-10-07 2000-04-13 Syngenta Participations Ag Therapeutically active proteins in plants
WO2000025574A1 (en) 1998-10-30 2000-05-11 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
CA2360670A1 (en) 1999-02-05 2000-08-10 Hilary Koprowski Production of biomedical peptides and proteins in plants using transcomplementation systems
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
EP1265840A2 (en) * 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
PT1294892E (pt) 2000-06-23 2008-01-16 Wyeth Corp Montagem de partículas semelhantes a vírus (vlps) de influenza de tipo selvagem e quiméricas
JP2004501648A (ja) 2000-06-26 2004-01-22 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム チオレドキシンおよび目的のポリペプチドの間に融合するユビキチンを含む三重融合タンパク質
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
CA2417214C (en) * 2000-08-03 2016-06-21 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
CA2471737C (en) 2001-12-26 2016-01-26 University Of Central Florida Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines
AU2003213022A1 (en) 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
WO2003105780A2 (en) * 2002-06-18 2003-12-24 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7282568B2 (en) 2002-12-16 2007-10-16 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)
ES2531125T3 (es) * 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
WO2004098533A2 (en) 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
KR20060029214A (ko) * 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
JP4999158B2 (ja) * 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
ES2427641T3 (es) 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
CA2816222A1 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP5096743B2 (ja) 2003-11-10 2012-12-12 アイコン・ジェネティクス・ゲーエムベーハー Ｒｎａウイルス由来植物発現システム
EP2570433A1 (en) 2003-11-14 2013-03-20 Emergent Product Development Gaithersburg Inc. Neutralizing human antibodies to anthrax toxin generated by recall technology
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
EP1769068B1 (en) 2004-02-20 2014-12-31 iBio, Inc. Systems and methods for clonal expression in plants
WO2005120567A2 (en) 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
US7888135B2 (en) * 2004-04-23 2011-02-15 University Of Georgia Research Foundation, Inc. Diagnostic assay for Trypanosoma cruzi infection
WO2005116258A2 (en) * 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase varians
EP1616959A1 (en) 2004-07-07 2006-01-18 Icon Genetics AG Biological safe transient protein expression in plants
WO2006124712A2 (en) 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
WO2007089753A2 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
BRPI0707785A2 (pt) 2006-02-13 2011-05-10 Fraunhofer Usa Inc produÇço de Ácidos nuclÉicos estranhos e polipeptÍdeos em sistemas de planta
AU2007215082B2 (en) * 2006-02-13 2012-07-12 Ibio, Inc. HPV antigens, vaccine compositions, and related methods
CN101454347B (zh) 2006-02-13 2013-07-24 美国弗劳恩霍夫股份有限公司 流感抗原、疫苗组合物和相关方法
EP2029167A4 (en) 2006-06-16 2010-06-16 Dow Agrosciences Llc NEW DNA SEQUENCES, VECTORS AND PROTEINS OF BIRD FLUID HEMOGGLUTININE
EP2056872A4 (en) 2006-08-09 2016-12-21 Medimmune Llc HEMAGGLUTININ AND NEURAMINIDASE VARIANTS OF FLU
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
AU2007295073A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
EP2086577B1 (en) 2006-10-16 2013-03-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Conjugates of the plasmodium falciparum surface protein pfs25 as malaria vaccine
EP2125886A2 (en) 2007-03-13 2009-12-02 Humabs LLC Antibodies against h5n1 strains of influenza a virus
WO2008134643A2 (en) 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8404252B2 (en) * 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009026397A2 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
KR20090042652A (ko) 2007-10-26 2009-04-30 주식회사 바이오노트 고병원성 조류 인플루엔자 바이러스 감염증을 위한 항체치료방법
BRPI0818268A2 (pt) 2007-10-31 2017-05-09 Univ Central Florida Res Found Inc antígenos de vacina humana derivados de cloroplasto contra a malária
US20120034253A1 (en) 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof

Also Published As

Publication number Publication date
JP2009502207A (ja) 2009-01-29
US20100239594A1 (en) 2010-09-23
BRPI0614475A2 (pt) 2011-03-29
KR101446025B1 (ko) 2014-10-01
CN101378781A (zh) 2009-03-04
CN101378781B (zh) 2013-08-07
CA2616859A1 (en) 2007-10-18
WO2007117264A2 (en) 2007-10-18
EP1919504A2 (en) 2008-05-14
KR20080045677A (ko) 2008-05-23
EP1919504B1 (en) 2013-10-16
AU2006341615A1 (en) 2007-10-18
IL189067A0 (en) 2008-06-05
WO2007117264A3 (en) 2008-05-22
US8962278B2 (en) 2015-02-24
BRPI0614475B1 (pt) 2018-04-24
CA2616859C (en) 2015-04-14

Similar Documents

Publication Publication Date Title
BRPI0614475B8 (pt) polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
AR127516A2 (es) VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN
BRPI0607486B8 (pt) anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
BRPI0610796B8 (pt) anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
BRPI0412138B8 (pt) método de selecionar um anticorpo monoclonal, método de selecionar um anticorpo monoclonal ou seu fragmento de ligação em antígeno, método de detectar a presença de células nk, e, método de purificar de uma amostra células nk
HN2004000285A (es) ANTICUERPOS DIRIGIDOS A c-MET
BRPI0606368A2 (pt) anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de hibridoma
HRP20080053A2 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CL2007003291A1 (es) Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
AR080942A1 (es) Produccion de proteinas heteromultimericas
UA116614C2 (uk) Антитіло до фактора d і його застосування
BRPI0816880A2 (pt) métodos para produzir uma planta com rendimento aumentado em comparação com uma planta do tipo selvagem correspondente, para produzir uma planta transgênica com rendimento aumentado em comparação com uma planta do tipo selvagem não transformada correspondente, para produzir uma composição agrícola, para identificar uma planta com um rendimento aumentado, e para aumentar o rendimento de uma população de plantas, molécula de ácido nucleico isolada, construção de ácido nucléico, vetor, processos para produzir um polipeptídeo, e para identificar um composto, polipeptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, pólen, progênie, material colhido ou planta, semente, parte de planta, planta transgênica, planta transgênica, núcleo de célula de planta transgênica, célula de planta transgênica, planta que compreende um ou mais de tais núcleos de célula de planta transgênica ou células de planta, progênie, semente ou pólen derivado de ou produzido por uma planta transgênica, composição, e, uso dos ácidos nucleicos.
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
AR047372A1 (es) Anticuerpos contra madcam
ECSP10010191A (es) Anticuerpos antimesotelina y usos de los mismos
EA200702087A1 (ru) Антитела против р-кадгерина
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
PE20091382A1 (es) Anticuerpos que se une a il-4 y/o a il-13
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25A Requested transfer of rights approved

Owner name: IBIO, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF